Join to View Full Profile
9200 W Wisconsin Ave# HematoloMilwaukee, WI 53226
Phone+1 414-805-0505
Fax+1 414-805-4606
Dr. Hari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Parameswaran Hari is an oncologist based in Milwaukee, WI, specializing in hematologic oncology. He completed his residency in internal medicine at Main Line Health System/Lankenau Medical Center and his fellowship in hematology and medical oncology at the Medical College of Wisconsin Affiliated Hospitals. Dr. Hari has expertise in metabolic syndrome, cardiac graft versus host disease, amyloidosis, and myelodysplasia. He has numerous publications in esteemed journals such as The New England Journal of Medicine and the Journal of Clinical Oncology, and he participates in various clinical trials focused on multiple myeloma and hemophilia. Dr. Hari has received recognition as a Regional Top Doctor and holds a CMS Meaningful Use Stage 1 Certification.
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2002 - 2004
Main Line Health System/Lankenau Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Kerala Medical CollegeClass of 1992
Certifications & Licensure
WI State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
- Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 13
- Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.Nirav N Shah, Alfredo S Colina, Bryon D Johnson, Aniko Szabo, Fateeha Furqan
Journal of Clinical Oncology. 2025-03-31 - 1 citationsProthrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.Wen Zhu, Yongwei Zheng, Mei Yu, Nathan Witman, Lu Zhou
Blood. 2025-02-06 - Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum
Journal for Immunotherapy of Cancer. 2025-01-28
Journal Articles
- Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated DonorsParameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
- Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple MyelomaParameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
- Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific MortalityParameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
- Join now to see all
Abstracts/Posters
- Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell TransplantationParameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).2019 ASCO Annual Meeting - 6/1/2019
- Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Interprofessional Collaboration Examples and How to Implement ItDecember 2nd, 2023- New FDA Approved Drug for Multiple MyelomaMarch 25th, 2021
- Hem/Onc Roundup: Financial Toxicity in MM Treatment, Personalizing Cancer Care, and MoreFebruary 19th, 2021
- Join now to see all
Other Languages
- French, Hindi, Tamil, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
